Naftopidil, a new adrenoceptor blocking agent with Ca(2+)-antagonistic properties: interaction with adrenoceptors.

J Cardiovasc Pharmacol

Pharmacological Laboratories, Boehringer Mannheim GmbH, Germany.

Published: December 1992

The interaction of naftopidil with adrenoceptors was studied in comparison to standard drugs. Naftopidil binds specifically to alpha 1-adrenoceptors. The Ki values are 58.3 nM for naftopidil, 0.43 nM for prazosin, and 197 nM for urapidil. The affinities of naftopidil to alpha 2- and beta-adrenoceptor sites are very low (> 6,000 and > 2,500 nM). Naftopidil relaxes aortic strips precontracted with norepinephrine concentration-dependently, and it shifts the concentration-response curve of norepinephrine in a parallel manner to the right. The pA2 values are 7.10 for naftopidil, 8.85 for prazosin, and 6.25 for urapidil. In pithed rats, naftopidil shifted the dose-response curve of methoxamine at equipotent hypotensive doses to the same extent to the right as does prazosin, but both drugs barely affected (in contrast to phentolamine) the response to norepinephrine. In concentrations that are about 10 times higher than those required for alpha 1-adrenoceptor blockade, naftopidil relaxes (in contrast to prazosin) aortic strips depolarized with K+, and it shifts Ca2+ concentration-response curves to the right (pA2 value of 5.90), thus suggesting Ca(2+)-channel-blocking activity. Both alpha-adrenoceptor and Ca(2+)-blocking activities are exerted to nearly the same extent by both stereoisomers. Naftipidil does not affect the response to isoprenaline-induced effects, indicating that the compound does not possess beta-blocking properties.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00005344-199212000-00023DOI Listing

Publication Analysis

Top Keywords

naftopidil
9
naftopidil relaxes
8
aortic strips
8
naftopidil adrenoceptor
4
adrenoceptor blocking
4
blocking agent
4
agent ca2+-antagonistic
4
ca2+-antagonistic properties
4
properties interaction
4
interaction adrenoceptors
4

Similar Publications

Targeting UGT2B15 and NR1H4 interaction: a novel therapeutic strategy for polycystic ovary syndrome using naftopidil enantiomers.

J Ovarian Res

January 2025

Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China.

Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder among women of reproductive age. It is characterized by hyperandrogenism, ovulatory dysfunction, and the presence of polycystic ovarian morphology (PCOM) on ultrasound, often accompanied by metabolic disturbances such as insulin resistance and obesity. Current treatments, including oral contraceptives and anti-androgen medications, often yield limited efficacy and undesirable side effects.

View Article and Find Full Text PDF

Association between alpha blocker use and the risk of fractures in patients with chronic kidney disease: a cohort study.

BMC Nephrol

December 2024

Department of Nephrology, Graduate School of Medicine, Nagoya University, Tsurumai-Cho 65, Showa-Ku, Nagoya City, Aichi Prefecture, Japan.

Article Synopsis
  • Alpha blockers (ABs) are commonly given to patients with chronic kidney disease (CKD) who often deal with high blood pressure, but the link between ABs and fracture risk is unclear, prompting this study.
  • The research analyzed a large cohort from a Japanese medical database, focusing on patients newly prescribed either ABs for hypertension or non-AB antihypertensive medications, with separate analyses for males and females.
  • The findings showed that while males had no increased fracture risk with AB use, females using ABs for voiding dysfunction exhibited a significant rise in fracture risk compared to those on antihypertensive ABs.
View Article and Find Full Text PDF

Despite the availability of various drugs for benign prostatic hyperplasia (BPH), alpha(α)-blockers are the preferred first-line treatment. However, there remains a scarcity of direct comparisons among various α-blockers. Therefore, this network meta-analysis (NMA) of randomized controlled trials (RCTs) aimed to evaluate the efficacy and safety of α-blockers in the management of BPH.

View Article and Find Full Text PDF

Sustainable technology for constructing Pd-catalyzed C-N bonds involving aliphatic amines is reported. A catalytic system that relies on , a known and , and a are combined, leading to a newly developed procedure. This new technology can be used in ocean water with equal effectiveness.

View Article and Find Full Text PDF

Although α-adrenoceptor (α-AR) antagonists used to treat benign prostatic hyperplasia can cause ejaculation disorders, the aetiology of this adverse event is still controversial. Therefore, we investigated the effects of antagonists with different affinities for α-AR subtypes on ejaculatory function and their mechanisms of action in normal rats. In the spontaneous seminal emission (SSE) test, systemically administered prazosin, terazosin, tamsulosin and naftopidil decreased the weight of ejaculated seminal material in a dose-dependent manner; the potency order was as follows: tamsulosin > terazosin > prazosin > naftopidil.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!